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We report a case of hydrocephalus due to brain metastasis from renal cell carcinoma treated with
axitinib. A 65-year-old man had undergone right radical nephrectomy for renal cell carcinoma in 2010.
The pathological diagnosis indicated clear cell carcinoma G3, pT1a. After adjuvant treatment with
interferon-α, computed tomography, in 2011, revealed multiple lung metastases. He was administered
sorafenib. Because of progressive lung metastases, sunitinib was administered. The lung metastases were
progressive and bone scan revealed multiple bone metastases. The patient was administered axitinib 10
mg/day in February 2014. Brain metastases were found in both the lateral ventricles in the same month
and were controlled using axitinib. The patient, however, experienced adverse events such as diarrhea and
hand foot syndrome, and the axitinib dosage was titrated. Cognitive function declined rapidly in August
2015. Brain magnetic resonance imaging revealed hydrocephalus due to brain metastasis from renal cell
carcinoma. Axitinib was administered again. Cognitive function improved within approximately 10 days.
Furthermore, hydrocephalus improved, and the patient was discharged on the 21st day.
(Hinyokika Kiyo 63 : 11-14, 2017 DOI : 10.14989/ActaUrolJap_63_1_11)











患 者 : 65歳，男性
既往歴 : HBV 陽性
現病歴 : 2010年11月に他院で右腎細胞癌に対し右根
治的腎摘出術を施行，病理組織学的に size は 7 cm
大，clear cell carcinoma G3 INFγ v（＋）pT1a であっ
た．術後補助療法としてインターフェロン α 療法を
導入したが，2011年 3月に両側肺野に多発肺転移（最




転移増悪傾向（最大 size 13 mm）のためスニチニブに




たため2014年 2月よりアキシチニブ 10 mg に変更し
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Fig. 1. Brain computed tomography ﬁndings.
Computed tomography showed metastatic





Fig. 2. a, b : Brain T2-weighted magnetic resonance
imaging and FLAIR ﬁndings. a : T2-
weighted magnetic resonance imaging
showed metastatic brain tumor and expan-
sion of the third ventricle on both sides. b :
T2-weighted magnetic resonance imaging
showed expansion on both sides of the
lateral ventricle.
泌62,08,0◆-3
Fig. 3. Brain computed tomography ﬁndings after
12 days of axitinib administration. Com-
puted tomography showed reduction in the
size of brain metastases on both sides.
る水頭症の診断に至り加療目的に入院となった．
入院時現象 :
意 識 : JCS I-2 GCS E4V4M6
血液検査 : WBC : 6,300/μl，Hb : 8.6 g/dl，Plt : 27.5
万/μl，T-Bil : 0.4，AST : 17 U/l，ALT : 12 U/l，LDH :
177 U/l，γ -GTP : 12 U/l，TP : 5. 6 g/dl，Alb : 2. 8 g/
dl，BUN : 11.8 mg/dl，Cr : 0.81 mg/dl，eGFR : 74.1
ml/min，CRP : 5. 51 mg/l，Na : 137 mEq/l，K : 4. 4
Eq/l，Cl : 101 mEq/l，TSH : 4.491 μIU/ml
画像検査所見 :
頭部単純 CT : 両側後頭葉に直径約 10 mm 大の転
移性脳腫瘍が認められ，周囲に浮腫を伴っており，脳
室の拡張が認められる（Fig. 1）．
頭部造影 MRI : 右側脳室内に約 17 mm 大，左側側













認めた（Fig. 3）．第15病日に再度，頭部造影 MRI 施
行し両側側脳室腫瘤の縮小，側脳室と第三脳室の正常









Fig. 4. a, b : Brain T2-weighted magnetic resonance
imaging and FLAIR ﬁndings after 15 days of
axitinib administration. a : T2-weighted
magnetic resonance imaging showed nor-
malization of the third ventricle. b : T2-
weighted magnetic resonance imaging
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